An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...
The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for ...
Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...
The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies ...
UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...